Exact Mass: 299.2096

Exact Mass Matches: 299.2096

Found 313 metabolites which its exact mass value is equals to given mass value 299.2096, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

indicine

BUTANOIC ACID, 2,3-DIHYDROXY-2-(1-METHYLETHYL)-, (2,3,5,7A-TETRAHYDRO-1-HYDROXY-1H-PYRROLIZIN-7-YL)METHYL ESTER, (1S-(1.ALPHA.,7(2R*,3S*),7A.ALPHA.))-

C15H25NO5 (299.1733)


Rinderine is a member of pyrrolizines. Rinderine is a natural product found in Chromolaena odorata, Eupatorium japonicum, and other organisms with data available.

   

Isolycopsamine

Isolycopsamine

C15H25NO5 (299.1733)


   

Ethylketocyclazocine

Ethylketocyclazocine

C19H25NO2 (299.1885)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Lycopsamine

[(1R,7aR)-1-hydroxy-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl]methyl (2S)-2-hydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO5 (299.1733)


Lycopsamine, also known as indicine or 9-viridiflorylretronecine, belongs to alkaloids and derivatives class of compounds. Those are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic propertiesand is also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus. Lycopsamine is soluble (in water) and a very weakly acidic compound (based on its pKa). Lycopsamine can be found in borage, which makes lycopsamine a potential biomarker for the consumption of this food product. CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2270

   

intermedine

9-(+)-Trachelanthylretronecine

C15H25NO5 (299.1733)


CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2293

   

2-Undecyl-4(1H)-quinolinone

2-undecyl-1,4-dihydroquinolin-4-one

C20H29NO (299.2249)


2-Undecyl-4(1H)-quinolinone is found in herbs and spices. 2-Undecyl-4(1H)-quinolinone is an alkaloid from and roots of Ruta graveolens (rue) (as the main component of an inseparable mixture of 2-alkylquinolones contg. the 2-dodecyl, 2-tridecyl and 2-tetradecyl homologues) (Rutaceae). Alkaloid from and roots of Ruta graveolens (rue) (as the main component of an inseparable mixture of 2-alkylquinolones contg. the 2-dodecyl, 2-tridecyl and 2-tetradecyl homologues) (Rutaceae). 2-Undecyl-4(1H)-quinolinone is found in herbs and spices.

   

Pentadecanoylglycine

2-[(1-Hydroxypentadecylidene)amino]acetate

C17H33NO3 (299.246)


Pentadecanoylglycine is an acylglycine with C-15 fatty acid group as the acyl moiety. Acylglycines 1 possess a common amidoacetic acid moiety and are normally minor metabolites of fatty acids. Elevated levels of certain acylglycines appear in the urine and blood of patients with various fatty acid oxidation disorders. They are normally produced through the action of glycine N-acyltransferase which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine ↔ CoA + N-acylglycine. Pentadecanoylglycine is an acylglycine with C-15 fatty acid group as the acyl moiety.

   

2-(3-carboxy-3-(trimethylammonio)propyl)-L-histidine

(3-{4-[(2S)-2-amino-2-carboxyethyl]-3H-imidazol-2-yl}-1-carboxypropyl)trimethylazanium

C13H23N4O4+ (299.1719)


2-(3-carboxy-3-(trimethylammonio)propyl)-l-histidine is part of the Protein modification pathway. It is a substrate for: Diphthine synthase.

   

Diphthine

[(1R)-3-{5-[(2S)-2-amino-2-carboxyethyl]-1H-imidazol-2-yl}-1-carboxypropyl]trimethylazanium

C13H23N4O4+ (299.1719)


This compound belongs to the family of Alpha Amino Acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).

   

3-Hydroxyocta-2,5-dienoylcarnitine

3-[(3-hydroxyocta-2,5-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO5 (299.1733)


3-hydroxyocta-2,5-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyocta-2,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxyocta-2,5-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyocta-2,5-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxyocta-2,6-dienoylcarnitine

3-[(3-hydroxyocta-2,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO5 (299.1733)


3-hydroxyocta-2,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyocta-2,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxyocta-2,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyocta-2,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxyocta-3,6-dienoylcarnitine

3-[(3-hydroxyocta-3,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO5 (299.1733)


3-hydroxyocta-3,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyocta-3,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxyocta-3,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyocta-3,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxyocta-2,4-dienoylcarnitine

3-[(3-Hydroxyocta-2,4-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C15H25NO5 (299.1733)


3-hydroxyocta-2,4-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyocta-2,4-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxyocta-2,4-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyocta-2,4-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,6Z)-3-Hydroxyocta-4,6-dienoylcarnitine

3-[(3-Hydroxyocta-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C15H25NO5 (299.1733)


(4Z,6Z)-3-hydroxyocta-4,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,6Z)-3-hydroxyocta-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,6Z)-3-hydroxyocta-4,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4Z,6Z)-3-hydroxyocta-4,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxyocta-3,5-dienoylcarnitine

3-[(3-hydroxyocta-3,5-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO5 (299.1733)


3-hydroxyocta-3,5-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyocta-3,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxyocta-3,5-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyocta-3,5-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2Z)-Non-2-enoylcarnitine

3-(Non-2-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H29NO4 (299.2096)


(2Z)-non-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2Z)-non-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z)-non-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z)-non-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-4-enoylcarnitine

3-(non-4-enoyloxy)-4-(trimethylazaniumyl)butanoate

C16H29NO4 (299.2096)


Non-4-enoylcarnitine is an acylcarnitine. More specifically, it is an non-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-5-enoylcarnitine

3-(non-5-enoyloxy)-4-(trimethylazaniumyl)butanoate

C16H29NO4 (299.2096)


Non-5-enoylcarnitine is an acylcarnitine. More specifically, it is an non-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-3-enoylcarnitine

3-(Non-3-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H29NO4 (299.2096)


Non-3-enoylcarnitine is an acylcarnitine. More specifically, it is an non-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-7-enoylcarnitine

3-(non-7-enoyloxy)-4-(trimethylazaniumyl)butanoate

C16H29NO4 (299.2096)


Non-7-enoylcarnitine is an acylcarnitine. More specifically, it is an non-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Non-6-enoylcarnitine

3-(Non-6-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H29NO4 (299.2096)


Non-6-enoylcarnitine is an acylcarnitine. More specifically, it is an non-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Valine

2-dodecanamido-3-methylbutanoic acid

C17H33NO3 (299.246)


N-lauroyl valine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Valine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Valine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Valine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Myristoyl Alanine

2-tetradecanamidopropanoic acid

C17H33NO3 (299.246)


N-myristoyl alanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Alanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Alanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Alanine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(+/-)-Ethylketocyclazocine

10-(cyclopropylmethyl)-1-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.0^{2,7}]trideca-2(7),3,5-trien-8-one

C19H25NO2 (299.1885)


   

(1R,9S)-10-(Cyclopropylmethyl)-12-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one

(1R,9S)-10-(Cyclopropylmethyl)-12-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one

C19H25NO2 (299.1885)


   

1-[1-(1-Benzothiophen-2-yl)cyclohexyl]piperidine

1-[1-(1-Benzothiophen-2-yl)cyclohexyl]piperidine

C19H25NS (299.1708)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

Benz(cd)indole-6-carboxamide, 4-(dipropylamino)-1,3,4,5-tetrahydro-

6-(dipropylamino)-2-azatricyclo[6.3.1.0^{4,12}]dodeca-1(12),3,8,10-tetraene-9-carboxamide

C18H25N3O (299.1998)


   

3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide

3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide

C20H29NO (299.2249)


   

Indicine

(1-Hydroxy-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl)methyl 2,3-dihydroxy-2-(propan-2-yl)butanoic acid

C15H25NO5 (299.1733)


   

3-Pyridinemethanol, 6-amino-alpha-(((1-methyl-4-phenylbutyl)amino)methyl)-

3-Pyridinemethanol, 6-amino-alpha-(((1-methyl-4-phenylbutyl)amino)methyl)-

C18H25N3O (299.1998)


   

Nylidrin

4-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]propyl}phenol

C19H25NO2 (299.1885)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AA - 2-amino-1-phenylethanol derivatives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

cyclo(D-Ile-L-Trp)

cyclo(D-Ile-L-Trp)

C17H21N3O2 (299.1634)


   

cyclo-L-Trp-L-Leu

cyclo-L-Trp-L-Leu

C17H21N3O2 (299.1634)


   

2-(Nonan-8-one)-4-methoxy-quinoline

2-(Nonan-8-one)-4-methoxy-quinoline

C19H25NO2 (299.1885)


   

DTXSID10707391

DTXSID10707391

C19H25NO2 (299.1885)


   
   

ATISINE, AZOMETHINE

ATISINE, AZOMETHINE

C20H29NO (299.2249)


   
   
   

Dehydroabietamide

Dehydroabietamide

C20H29NO (299.2249)


   

N-(3-Hydroxydodecanoyl)-DL-homoserine lactone

N-(3-Hydroxydodecanoyl)-DL-homoserine lactone

C16H29NO4 (299.2096)


   

nylidrin

nylidrin

C19H25NO2 (299.1885)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AA - 2-amino-1-phenylethanol derivatives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents CONFIDENCE standard compound; INTERNAL_ID 6; HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) INTERNAL_ID 6; CONFIDENCE standard compound; HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu); Flow Injection CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu)

   

Haminol C|Haminol-C

Haminol C|Haminol-C

C19H25NO2 (299.1885)


   

mirabilin I

mirabilin I

C19H29N3 (299.2361)


   

(+-)-7,8,9-trimethyl-eleocarpine|(+-)-Elaeocarpin|6a,11,12a,12b-tetramethyl-(6ar,12at,12bc)-1,2,3,5,6,6a,12a,12b-octahydro-chromeno[2,3-g]indolizin-12-one

(+-)-7,8,9-trimethyl-eleocarpine|(+-)-Elaeocarpin|6a,11,12a,12b-tetramethyl-(6ar,12at,12bc)-1,2,3,5,6,6a,12a,12b-octahydro-chromeno[2,3-g]indolizin-12-one

C19H25NO2 (299.1885)


   

tetradeca-2t,6t,8t-12c-tetraen-10-ynoic isobutyl amide

tetradeca-2t,6t,8t-12c-tetraen-10-ynoic isobutyl amide

C20H29NO (299.2249)


   

3,4-Dihydro,1-hydroxy-Dictyolomide A|dictylomide B

3,4-Dihydro,1-hydroxy-Dictyolomide A|dictylomide B

C19H25NO2 (299.1885)


   
   

Veatchine azomethine

Veatchine azomethine

C20H29NO (299.2249)


   

Me ester,(E)-oxime-2-Oxo-hexadecanoic acid

Me ester,(E)-oxime-2-Oxo-hexadecanoic acid

C17H33NO3 (299.246)


   

(2E,6E,8E)-2,6,8-Hexadecatrien-10-insaeure-pyrrolidid

(2E,6E,8E)-2,6,8-Hexadecatrien-10-insaeure-pyrrolidid

C20H29NO (299.2249)


   

hexadeca-9Z-en-10-ynoic acid pyrrolide

hexadeca-9Z-en-10-ynoic acid pyrrolide

C20H29NO (299.2249)


   

(2S,3S,6E)-N,N-dimethyl-2-[(R)-methylsulfinyl]tetradeca-6,13-dien-3-amine|(2S,3S,6E)-N,N-dimethyl-2-[(S)-methylsulfinyl]tetradeca-6,13-dien-3-amine|aplisulfamine A|aplisulfamine B

(2S,3S,6E)-N,N-dimethyl-2-[(R)-methylsulfinyl]tetradeca-6,13-dien-3-amine|(2S,3S,6E)-N,N-dimethyl-2-[(S)-methylsulfinyl]tetradeca-6,13-dien-3-amine|aplisulfamine A|aplisulfamine B

C17H33NOS (299.2283)


   
   

(3R,5S)-3-methyl-5-((5E)-pentadec-5-ene-7,9-diynyl)-pyrrolidin-2-one

(3R,5S)-3-methyl-5-((5E)-pentadec-5-ene-7,9-diynyl)-pyrrolidin-2-one

C20H29NO (299.2249)


   

1-Methyl-2-decylquinoline-4(1H)-one

1-Methyl-2-decylquinoline-4(1H)-one

C20H29NO (299.2249)


   

2-Methylpropylamide-(2E,9Z)-2,9-Hexadecadiene-12,14-diynoic acid|hexadeca-2E,9Z-dien-12,14-diynoic acid isobutylamide

2-Methylpropylamide-(2E,9Z)-2,9-Hexadecadiene-12,14-diynoic acid|hexadeca-2E,9Z-dien-12,14-diynoic acid isobutylamide

C20H29NO (299.2249)


   

Haminol 6|Haminol-6

Haminol 6|Haminol-6

C19H25NO2 (299.1885)


   

1-Methyl-2-(8-oxononyl)quinoline-4(1H)-one

1-Methyl-2-(8-oxononyl)quinoline-4(1H)-one

C19H25NO2 (299.1885)


   

Haminol 2|haminol acetate|Haminol-2

Haminol 2|haminol acetate|Haminol-2

C19H25NO2 (299.1885)


   

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-3-methyl-2-butenamide

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-3-methyl-2-butenamide

C19H25NO2 (299.1885)


   

Trachelanthamidine 2S-hydroxy-2S-(1S-hydroxyethyl)-4-methylpentanoyl ester

Trachelanthamidine 2S-hydroxy-2S-(1S-hydroxyethyl)-4-methylpentanoyl ester

C16H29NO4 (299.2096)


   

(2E,7Z)-2,7-Hexadecadien-10-insaeure-(2,3-didehydropyrrolidid)|(2E,7Z)-2,7-Hexadecadien-10-insaeure-<2,3-didehydropyrrolidid>

(2E,7Z)-2,7-Hexadecadien-10-insaeure-(2,3-didehydropyrrolidid)|(2E,7Z)-2,7-Hexadecadien-10-insaeure-<2,3-didehydropyrrolidid>

C20H29NO (299.2249)


   

Leptophyllin B

Leptophyllin B

C17H33NO3 (299.246)


   

Viridiflorine

Viridiflorine

C16H29NO4 (299.2096)


   

Haminol B|Haminol-B

Haminol B|Haminol-B

C19H25NO2 (299.1885)


   

glaciapyrrole C

glaciapyrrole C

C19H25NO2 (299.1885)


   
   
   
   
   
   

Intermedina

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, [(1R,7aR)-2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl]methyl ester, (2S,3R)-; Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester, [1R-[1?,7(2S*,3R*),7a?]]-; Intermedine (7CI,8CI); (+)-Intermedine; 3-epi-Lycopsamine

C15H25NO5 (299.1733)


Intermedine is a carboxylic ester compound formed from condensation between retronecine and (2S,3R)-2,3-dihydroxy-2-isopropylbutanoic acid. It is a member of pyrrolizines, an azabicycloalkane and a carboxylic ester. Intermedine is a natural product found in Eupatorium cannabinum, Chromolaena odorata, and other organisms with data available. See also: Comfrey Leaf (part of); Comfrey Root (part of).

   

indicine

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester, [1R-[1?,7(2S*,3S*),7a?]]-; Lycopsamine (7CI,8CI); (+)-Lycopsamine; 3-epi-Intermedine; Retronecine 9-((-)-viridiflorate)

C15H25NO5 (299.1733)


Lycopsamine is a member of pyrrolizines. Lycopsamine is a natural product found in Brickellia grandiflora, Eupatorium cannabinum, and other organisms with data available. See also: Comfrey Leaf (part of); Comfrey Root (part of); Borage (part of).

   

UHQ (mixed MS2 C11:db:UHQ)

UHQ (mixed MS2 C11:db:UHQ)

C20H29NO (299.2249)


   

PYR_300.1709_10.6

PYR_300.1709_10.6

C17H21N3O2 (299.1634)


CONFIDENCE Identification confirmed with Reference Standard synthesized at Eawag (Level 1); INTERNAL_ID 1710

   

3-hydroxy-C12 homoserine lactone

3-Hydroxy-N-(2-oxotetrahydrofuran-3-yl)dodecanamide

C16H29NO4 (299.2096)


CONFIDENCE standard compound; INTERNAL_ID 217

   

Rinderine

Rinderine

C15H25NO5 (299.1733)


Annotation level-1

   

echinatine

echinatine

C15H25NO5 (299.1733)


Origin: Plant; SubCategory_DNP: Alkaloids derived from ornithine, Pyrrolizidine alkaloids

   

nonylphenazolone

nonylphenazolone

C19H25NO2 (299.1885)


   
   
   
   
   
   
   
   
   
   
   

4-Hydroxy-2-undecylquinoline

2-undecyl-1,4-dihydroquinolin-4-one

C20H29NO (299.2249)


   

2-(3-carboxy-3-(trimethylammonio)propyl)-L-histidine

(3-{5-[(2S)-2-amino-2-carboxyethyl]-1H-imidazol-2-yl}-1-carboxypropyl)trimethylazanium

C13H23N4O4 (299.1719)


   

3OH-C12-HSL

N-(3-hydroxy-dodecanoyl)-homoserine lactone

C16H29NO4 (299.2096)


   

CIS-6,9,12,15-OCTADECATETRAENOIC ACID*SO DIUM

CIS-6,9,12,15-OCTADECATETRAENOIC ACID*SO DIUM

C18H28NaO2 (299.1987)


   
   

7-Ethoxycarbonyl-9-(ethoxycarbonylmethyl)-9-azabicyclo[3,3,1]nonan-3-ol

7-Ethoxycarbonyl-9-(ethoxycarbonylmethyl)-9-azabicyclo[3,3,1]nonan-3-ol

C15H25NO5 (299.1733)


   

4-Cyanophenyl trans-4-pentylcyclohexanecarboxylate

4-Cyanophenyl trans-4-pentylcyclohexanecarboxylate

C19H25NO2 (299.1885)


   

Propinetidine

Propinetidine

C19H25NO2 (299.1885)


   

(-)-Tramadol Hydrochloride

(-)-tramadol, hydrochloride

C16H26ClNO2 (299.1652)


   

1H-IMIDAZO[4,5-C]QUINOLINE-1-PROPANAMINE,4-AMINO-2-(ETHOXYMETHYL)

1H-IMIDAZO[4,5-C]QUINOLINE-1-PROPANAMINE,4-AMINO-2-(ETHOXYMETHYL)

C16H21N5O (299.1746)


   

N2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYL)PYRIMIDINE-2,5-DIAMINE

N2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYL)PYRIMIDINE-2,5-DIAMINE

C16H21N5O (299.1746)


   
   
   
   

2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-methylpropyl 2-methylprop-2-enoate

2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-methylpropyl 2-methylprop-2-enoate

C16H29NO4 (299.2096)


   

5-BOC-1-PHENYL-1,4,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDINE

5-BOC-1-PHENYL-1,4,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDINE

C17H21N3O2 (299.1634)


   

1-BOC-3-(3-MORPHOLIN-4-YL-PROPYLAMINO)-AZETIDINE

1-BOC-3-(3-MORPHOLIN-4-YL-PROPYLAMINO)-AZETIDINE

C15H29N3O3 (299.2209)


   

Urea, N-cyclopropyl-N-[(1,2-dihydro-6-methyl-2-oxo-3-quinolinyl)methyl]-N,N-dimethyl- (9CI)

Urea, N-cyclopropyl-N-[(1,2-dihydro-6-methyl-2-oxo-3-quinolinyl)methyl]-N,N-dimethyl- (9CI)

C17H21N3O2 (299.1634)


   

4-(2-ETHOXYCARBONYL-ACETYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER

4-(2-ETHOXYCARBONYL-ACETYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER

C15H25NO5 (299.1733)


   

Desvenlafaxine hydrochloride

Desvenlafaxine hydrochloride

C16H26ClNO2 (299.1652)


   

1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexan-1-ol,hydrochloride

1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexan-1-ol,hydrochloride

C16H26ClNO2 (299.1652)


   
   

N-(1-oxotetradecyl)sarcosine

N-(1-oxotetradecyl)sarcosine

C17H33NO3 (299.246)


   

1-(TRIISOPROPYLSILYL)-1H-PYRROLO[2,3-B]PYRIDINE-4-CARBONITRILE

1-(TRIISOPROPYLSILYL)-1H-PYRROLO[2,3-B]PYRIDINE-4-CARBONITRILE

C17H25N3Si (299.1818)


   

TRAMADOL HYDROCHLORIDE

(+)-Tramadol Hydrochloride

C16H26ClNO2 (299.1652)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

1-benzyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester

1-benzyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester

C18H26BNO2 (299.2056)


   

1-Benzyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine

1-Benzyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine

C18H26BNO2 (299.2056)


   

(S)-[1-([1,4]DIAZEPANE-1-CARBONYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER

(S)-[1-([1,4]DIAZEPANE-1-CARBONYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER

C15H29N3O3 (299.2209)


   

3-Ethyl 1-(2-methyl-2-propanyl) 3-isopropyl-1,3-piperidinedicarbo xylate

3-Ethyl 1-(2-methyl-2-propanyl) 3-isopropyl-1,3-piperidinedicarbo xylate

C16H29NO4 (299.2096)


   

Piperazine, 1-[(3-formyl-2-methyl-1H-indol-1-yl)acetyl]-4-methyl- (9CI)

Piperazine, 1-[(3-formyl-2-methyl-1H-indol-1-yl)acetyl]-4-methyl- (9CI)

C17H21N3O2 (299.1634)


   

Butyl 2-methyl-2-propenoate, N-[(2-methylpropoxy)methyl]-2-propenamide polymer

Butyl 2-methyl-2-propenoate, N-[(2-methylpropoxy)methyl]-2-propenamide polymer

C16H29NO4 (299.2096)


   

butyl prop-2-enoate,methyl 2-methylprop-2-enoate,prop-2-enamide

butyl prop-2-enoate,methyl 2-methylprop-2-enoate,prop-2-enamide

C15H25NO5 (299.1733)


   

1-Boc-2-[4-(2-pyridinyl)benzylidene]hydrazine

1-Boc-2-[4-(2-pyridinyl)benzylidene]hydrazine

C17H21N3O2 (299.1634)


   

Azepino[4,5-b]indole-5-carboxylic acid, 9-amino-1,2,3,6-tetrahydro-1,1-dimethyl-, ethyl ester

Azepino[4,5-b]indole-5-carboxylic acid, 9-amino-1,2,3,6-tetrahydro-1,1-dimethyl-, ethyl ester

C17H21N3O2 (299.1634)


   

2-Methyl-2-propanyl 4-(1H-pyrrolo[3,2-b]pyridin-3-yl)-3,6-dihydro -1(2H)-pyridinecarboxylate

2-Methyl-2-propanyl 4-(1H-pyrrolo[3,2-b]pyridin-3-yl)-3,6-dihydro -1(2H)-pyridinecarboxylate

C17H21N3O2 (299.1634)


   

Methanone, (3-ethyl-5-methyl-4-isoxazolyl)(4-phenyl-1-piperazinyl)

Methanone, (3-ethyl-5-methyl-4-isoxazolyl)(4-phenyl-1-piperazinyl)

C17H21N3O2 (299.1634)


   

1-Oxa-8-azaspiro[4.5]decane-3-acetic acid, 8-[(1,1-dimethylethoxy)carbonyl]-

1-Oxa-8-azaspiro[4.5]decane-3-acetic acid, 8-[(1,1-dimethylethoxy)carbonyl]-

C15H25NO5 (299.1733)


   

3,3-DIMETHOXY-ALPHA-METHYLDIPHENETHYLAMINE HYDROCHLORIDE

3,3-DIMETHOXY-ALPHA-METHYLDIPHENETHYLAMINE HYDROCHLORIDE

C19H25NO2 (299.1885)


   

(S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate

(S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate

C16H29NO4 (299.2096)


   

N-Tetradecanoyl-L-alanine

N-Tetradecanoyl-L-alanine

C17H33NO3 (299.246)


   

N-Dodecanoyl-L-valine

N-Dodecanoyl-L-valine

C17H33NO3 (299.246)


   

Ethyl 1-Boc-4-iso-propyl-4-piperidinecarboxylate

Ethyl 1-Boc-4-iso-propyl-4-piperidinecarboxylate

C16H29NO4 (299.2096)


   

7-Boc-3-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine

7-Boc-3-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine

C17H21N3O2 (299.1634)


   
   

5-METHYL-2-((3-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4(3H)-ONE

5-METHYL-2-((3-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4(3H)-ONE

C16H21N5O (299.1746)


   

TRIMETHYL[3-(TRIETHOXYSILYL)PROPYL]AMMONIUM CHLORIDE

TRIMETHYL[3-(TRIETHOXYSILYL)PROPYL]AMMONIUM CHLORIDE

C12H30ClNO3Si (299.1683)


   

TERT-BUTYL 3-PHENYL-6,7-DIHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE-5(4H)-CARBOXYLATE

TERT-BUTYL 3-PHENYL-6,7-DIHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE-5(4H)-CARBOXYLATE

C17H21N3O2 (299.1634)


   

PHTHALIMIDE DBU SALT

PHTHALIMIDE DBU SALT

C17H21N3O2 (299.1634)


   

6-[4-[2-(dimethylamino)ethyl]-5-ethyl-2-methoxyphenyl]pyridin-2-amine

6-[4-[2-(dimethylamino)ethyl]-5-ethyl-2-methoxyphenyl]pyridin-2-amine

C18H25N3O (299.1998)


   

1-benzhydryl-3-phenylazetidine

1-benzhydryl-3-phenylazetidine

C22H21N (299.1674)


   

(R)-(7-Methyl-1,4-diazepan-1-yl)(5-Methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)Methanone

(R)-(7-Methyl-1,4-diazepan-1-yl)(5-Methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)Methanone

C16H21N5O (299.1746)


   

9-(4-(tert-butyl)phenyl)-9H-carbazole

9-(4-(tert-butyl)phenyl)-9H-carbazole

C22H21N (299.1674)


   

(S)-2-{[(((1R,2R)-2-(allyloxy)cyclopentyl)oxy)carbonyl]amino}-3,3-dimethylbutanoic acid

(S)-2-{[(((1R,2R)-2-(allyloxy)cyclopentyl)oxy)carbonyl]amino}-3,3-dimethylbutanoic acid

C15H25NO5 (299.1733)


   

7-(5-Ethyl-2-nonanyl)-8-quinolinol

7-(5-Ethyl-2-nonanyl)-8-quinolinol

C20H29NO (299.2249)


   

3-(2-ethoxycarbonyl-acetyl)-piperidine-1-carboxylic acid tert-butyl ester

3-(2-ethoxycarbonyl-acetyl)-piperidine-1-carboxylic acid tert-butyl ester

C15H25NO5 (299.1733)


   

Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-(decyloxy)-, ammonium salt

Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-(decyloxy)-, ammonium salt

C12H29NO5S (299.1766)


   

3-HYDROXY-N-((S)-2-OXOTETRAHYDROFURAN-3-YL)DODECANAMIDE

3-HYDROXY-N-((S)-2-OXOTETRAHYDROFURAN-3-YL)DODECANAMIDE

C16H29NO4 (299.2096)


   

4-Carboxy-5-(1-pentyl)hexylsulfanyl-1,2,3-triazole

4-Carboxy-5-(1-pentyl)hexylsulfanyl-1,2,3-triazole

C14H25N3O2S (299.1667)


   

Emixustat hydrochloride

Emixustat hydrochloride

C16H26ClNO2 (299.1652)


C78283 - Agent Affecting Organs of Special Senses

   

2-[(3S)-3-carboxy-3-(trimethylammonio)propyl]-L-histidine

2-[(3S)-3-carboxy-3-(trimethylammonio)propyl]-L-histidine

C13H23N4O4+ (299.1719)


   

Retinamide

Retinamide

C20H29NO (299.2249)


D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D000970 - Antineoplastic Agents

   

3-Cyclopropylmethyl-5-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2H-2,6-methano-benzo[d]azocin-1-one

3-Cyclopropylmethyl-5-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2H-2,6-methano-benzo[d]azocin-1-one

C19H25NO2 (299.1885)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

4-(Dipropylamino)-1,3,4,5-tetrahydrobenz(cd)indole-6-carboxamide

4-(Dipropylamino)-1,3,4,5-tetrahydrobenz(cd)indole-6-carboxamide

C18H25N3O (299.1998)


   

(2S)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid

(2S)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid

C14H25N3O4 (299.1845)


   

2-[[6-Amino-2-[3-(dimethylamino)propylamino]-5-nitro-4-pyrimidinyl]amino]ethanol

2-[[6-Amino-2-[3-(dimethylamino)propylamino]-5-nitro-4-pyrimidinyl]amino]ethanol

C11H21N7O3 (299.1706)


   

Arginine beta-naphthylamide

Arginine beta-naphthylamide

C16H21N5O (299.1746)


   

1-Cyclohexyl-3-[(1,2-dimethyl-5-indolyl)methyl]urea

1-Cyclohexyl-3-[(1,2-dimethyl-5-indolyl)methyl]urea

C18H25N3O (299.1998)


   

N,N-diethyl-2-(4-methyl-1-piperazinyl)-4-quinazolinamine

N,N-diethyl-2-(4-methyl-1-piperazinyl)-4-quinazolinamine

C17H25N5 (299.211)


   

N-(2-((4-Methoxybenzyl)(2-pyridinyl)amino)ethyl)-N-methylformamide

N-(2-((4-Methoxybenzyl)(2-pyridinyl)amino)ethyl)-N-methylformamide

C17H21N3O2 (299.1634)


   

2-(beta-Dimethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole

2-(beta-Dimethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole

C18H25N3O (299.1998)


   

[(1S,7aR)-1-hydroxy-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl]methyl 2,3-dihydroxy-2-(propan-2-yl)butanoate

[(1S,7aR)-1-hydroxy-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl]methyl 2,3-dihydroxy-2-(propan-2-yl)butanoate

C15H25NO5 (299.1733)


   

all-trans-Retinoate

all-trans-Retinoate

C20H27O2- (299.2011)


A retinoate that is the conjugate base of all-trans-retinoic acid.

   

18-Hydroxystearate

18-Hydroxystearate

C18H35O3- (299.2586)


An omega-hydroxy fatty acid anion that is the conjugate base of 18-hydroxystearic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

fumigaclavine A(1+)

fumigaclavine A(1+)

C18H23N2O2+ (299.1759)


An ammonium ion obtained by the protonation of the tertiary amino group of fumigaclavine A; major species at pH 7.3.

   

3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate

3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate

C20H27O2- (299.2011)


COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

(S)-2-Hydroxystearate

(S)-2-Hydroxystearate

C18H35O3- (299.2586)


   

(R)-10-Hydroxystearate

(R)-10-Hydroxystearate

C18H35O3- (299.2586)


   

9-Hydroxystearate

9-Hydroxystearate

C18H35O3- (299.2586)


   

13-cis-Retinoate

13-cis-Retinoate

C20H27O2- (299.2011)


   

(R)-2-Hydroxystearate

(R)-2-Hydroxystearate

C18H35O3- (299.2586)


   
   

(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate

(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate

C20H27O2- (299.2011)


   

(S,S)-2,5-di-(p-hydroxybenzyl)piperazine

(S,S)-2,5-di-(p-hydroxybenzyl)piperazine

C18H23N2O2+ (299.1759)


   

(2Z,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate

(2Z,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate

C20H27O2- (299.2011)


   

(2S)-2-[[(2E,6E)-8-hydroxy-3,7-dimethylocta-2,6-dienyl]amino]pentanedioic acid

(2S)-2-[[(2E,6E)-8-hydroxy-3,7-dimethylocta-2,6-dienyl]amino]pentanedioic acid

C15H25NO5 (299.1733)


   

Non-4-enoylcarnitine

Non-4-enoylcarnitine

C16H29NO4 (299.2096)


   

Non-5-enoylcarnitine

Non-5-enoylcarnitine

C16H29NO4 (299.2096)


   

Non-3-enoylcarnitine

Non-3-enoylcarnitine

C16H29NO4 (299.2096)


   

Non-7-enoylcarnitine

Non-7-enoylcarnitine

C16H29NO4 (299.2096)


   

Non-6-enoylcarnitine

Non-6-enoylcarnitine

C16H29NO4 (299.2096)


   

(2Z)-Non-2-enoylcarnitine

(2Z)-Non-2-enoylcarnitine

C16H29NO4 (299.2096)


   

3-Hydroxyocta-2,5-dienoylcarnitine

3-Hydroxyocta-2,5-dienoylcarnitine

C15H25NO5 (299.1733)


   

3-Hydroxyocta-2,6-dienoylcarnitine

3-Hydroxyocta-2,6-dienoylcarnitine

C15H25NO5 (299.1733)


   

3-Hydroxyocta-3,6-dienoylcarnitine

3-Hydroxyocta-3,6-dienoylcarnitine

C15H25NO5 (299.1733)


   

3-Hydroxyocta-2,4-dienoylcarnitine

3-Hydroxyocta-2,4-dienoylcarnitine

C15H25NO5 (299.1733)


   

3-Hydroxyocta-3,5-dienoylcarnitine

3-Hydroxyocta-3,5-dienoylcarnitine

C15H25NO5 (299.1733)


   

(4Z,6Z)-3-Hydroxyocta-4,6-dienoylcarnitine

(4Z,6Z)-3-Hydroxyocta-4,6-dienoylcarnitine

C15H25NO5 (299.1733)


   

9-cis-Retinoate

9-cis-Retinoate

C20H27O2- (299.2011)


A retinoate that is the conjugate base of 9-cis-retinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

2-hydroxystearate

2-hydroxystearate

C18H35O3- (299.2586)


   

3-Hydroxyoctadecanoate

3-Hydroxyoctadecanoate

C18H35O3- (299.2586)


   

12-Hydroxyoctadecanoate

12-Hydroxyoctadecanoate

C18H35O3- (299.2586)


A hydroxy saturated fatty acid anion that is the conjugate base of 12-hydroxyoctadecanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

11-cis-Retinoate

11-cis-Retinoate

C20H27O2- (299.2011)


A retinoate that is the conjugate base of 11-cis-retinoic acid, obtaained by deprotonation of the carboxy group; major species at pH 7.3.

   

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate

C20H27O2- (299.2011)


   

5-Hydroxyoctadecanoate

5-Hydroxyoctadecanoate

C18H35O3- (299.2586)


   

10-Hydroxyoctadecanoate

10-Hydroxyoctadecanoate

C18H35O3- (299.2586)


A hydroxy saturated fatty acid anion resulting from the deprotonation of the carboxy group of 10-hydroxyoctadecanoic acid.

   

13-Hydroxyoctadecanoate

13-Hydroxyoctadecanoate

C18H35O3- (299.2586)


   

(2R)-1-[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid

(2R)-1-[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid

C14H25N3O4 (299.1845)


   

(5S)-1-(4-cyclohexylbutyl)-5-phenyl-4,5-dihydroimidazol-2-amine

(5S)-1-(4-cyclohexylbutyl)-5-phenyl-4,5-dihydroimidazol-2-amine

C19H29N3 (299.2361)


   

N-(1-butyl-2-benzimidazolyl)cyclohexanecarboxamide

N-(1-butyl-2-benzimidazolyl)cyclohexanecarboxamide

C18H25N3O (299.1998)


   

1-[2-(diethylamino)ethyl]-5,6-dimethyl-1H-pyrrolo[1,2,3-de]quinoxalin-2(3H)-one

1-[2-(diethylamino)ethyl]-5,6-dimethyl-1H-pyrrolo[1,2,3-de]quinoxalin-2(3H)-one

C18H25N3O (299.1998)


   

1-[4-[4-(2-Furanylmethylamino)phenyl]-1-piperazinyl]ethanone

1-[4-[4-(2-Furanylmethylamino)phenyl]-1-piperazinyl]ethanone

C17H21N3O2 (299.1634)


   
   
   
   
   
   
   
   
   
   

Isoleucyl-alanyl-proline

Isoleucyl-alanyl-proline

C14H25N3O4 (299.1845)


   

(S)-carazolol(1+)

(S)-carazolol(1+)

C18H23N2O2+ (299.1759)


   

(E)-Delta-methoxymycolate

(E)-Delta-methoxymycolate

C17H31O4- (299.2222)


   

2,6-Ditert-butyl-4-(4-methoxyphenyl)pyrylium

2,6-Ditert-butyl-4-(4-methoxyphenyl)pyrylium

C20H27O2+ (299.2011)


   

3-(Diethylamino)-1-(4-fluorophenyl)-2-phenyl-1-propanone

3-(Diethylamino)-1-(4-fluorophenyl)-2-phenyl-1-propanone

C19H22FNO (299.1685)


   

cyclo-(D-Leu-L-Trp)

cyclo-(D-Leu-L-Trp)

C17H21N3O2 (299.1634)


   

N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]acetamide

N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]acetamide

C17H33NO3 (299.246)


   

(3R,6S)-3-butan-2-yl-6-(1H-indol-3-ylmethyl)piperazine-2,5-dione

(3R,6S)-3-butan-2-yl-6-(1H-indol-3-ylmethyl)piperazine-2,5-dione

C17H21N3O2 (299.1634)


   

N-[(E)-1,3-dihydroxyoct-4-en-2-yl]nonanamide

N-[(E)-1,3-dihydroxyoct-4-en-2-yl]nonanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxynon-4-en-2-yl]octanamide

N-[(E)-1,3-dihydroxynon-4-en-2-yl]octanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]propanamide

N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]propanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxytridec-4-en-2-yl]butanamide

N-[(E)-1,3-dihydroxytridec-4-en-2-yl]butanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxyundec-4-en-2-yl]hexanamide

N-[(E)-1,3-dihydroxyundec-4-en-2-yl]hexanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxydec-4-en-2-yl]heptanamide

N-[(E)-1,3-dihydroxydec-4-en-2-yl]heptanamide

C17H33NO3 (299.246)


   

N-[(E)-1,3-dihydroxydodec-4-en-2-yl]pentanamide

N-[(E)-1,3-dihydroxydodec-4-en-2-yl]pentanamide

C17H33NO3 (299.246)


   

Propanoic acid, 2-[(1-cyclohexylethyl)carbamoyl]-, trimethylsilyl ester

Propanoic acid, 2-[(1-cyclohexylethyl)carbamoyl]-, trimethylsilyl ester

C15H29NO3Si (299.1917)


   

CID 443409

CID 443409

C19H25NO2 (299.1885)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

(R)-10-hydroxyoctadecanoate

(R)-10-hydroxyoctadecanoate

C18H35O3 (299.2586)


A hydroxy monocarboxylic acid anion resulting from the removal of the proton from the carboxy group of (R)-10-hydroxyoctadecanoic acid.

   

Diphthine

Diphthine

C13H23N4O4 (299.1719)


A quaternary ammonium ion consisting of L-histidine with a 3-(trimethylammonio)-3-carboxypropyl group at the 2-position of the the imidazole ring.

   

BTCP HCl

1-[1-(1-Benzothiophen-2-yl)cyclohexyl]piperidine

C19H25NS (299.1708)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

2-Undecyl-4(1H)-quinolinone

2-Undecyl-4(1H)-quinolinone

C20H29NO (299.2249)


   

Pentadecanoylglycine

Pentadecanoylglycine

C17H33NO3 (299.246)


   

2-(3-carboxy-3-(trimethylammonio)propyl)-L-histidine

2-(3-carboxy-3-(trimethylammonio)propyl)-L-histidine

C13H23N4O4+ (299.1719)


   

2-Hydroxyoctadecanoate

2-Hydroxyoctadecanoate

C18H35O3 (299.2586)


A 2-hydroxy fatty acid anion that is the conjugate base of 2-hydroxyoctadecanoic acid (stearic acid), obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

3-Hydroxy-N-(2-oxotetrahydrofuran-3-yl)dodecanamide

3-Hydroxy-N-(2-oxotetrahydrofuran-3-yl)dodecanamide

C16H29NO4 (299.2096)


   

Dehydroabietate

Dehydroabietate

C20H27O2 (299.2011)


A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group.

   

3-hydroxystearate

3-hydroxystearate

C18H35O3 (299.2586)


A 3-hydroxy fatty acid anion that is the conjugate base of 3-hydroxystearic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

(R)-2-hydroxyoctadecanoate

(R)-2-hydroxyoctadecanoate

C18H35O3 (299.2586)


A 2-hydroxyoctadecanoate that has R configuration. The conjugate base of (R)-2-hydroxyoctadecanoic acid.

   

(S)-2-Hydroxyoctadecanoate

(S)-2-Hydroxyoctadecanoate

C18H35O3 (299.2586)


A 2-hydroxyoctadecanoate that has S configuration. The conjugate base of (S)-2-hydroxystearic acid obtained via deprotonation of the carboxy group; major species at pH 7.3.

   

NA-Ala 14:0

NA-Ala 14:0

C17H33NO3 (299.246)


   

NA-Gly 15:0

NA-Gly 15:0

C17H33NO3 (299.246)


   

NA-Ile 11:0

NA-Ile 11:0

C17H33NO3 (299.246)


   

NA-Leu 11:0

NA-Leu 11:0

C17H33NO3 (299.246)


   

NA-Val 12:0

NA-Val 12:0

C17H33NO3 (299.246)


   
   
   
   
   
   
   

Undecyl-(1H-quinolinone)

Undecyl-(1H-quinolinone)

C20H29NO (299.2249)


   

U93631

U93631

C17H21N3O2 (299.1634)


U93631 is a GABAA receptor ligand of novel chemical structure with IC50 of 100 nM,and has been shown to induce a rapid, time-dependent decay of GABA-induced whole-cell Cl-currents in recombinant GABAA receptors. target: GABAA receptor IC 50: GABAA receptor[1] In vitro: In the presence of U93631 at 5 UM, the peak amplitude decreased as a function of GABA concentration, with the half-maximal inhibitory concentration being approximately 100 nM, which is close to the Kd for the high affinity GABA site(85 nM). It appears that the drug interacts with GABA-bound receptors (at least monoliganded) and accelerates receptor desensitization, rather than acting as an open channel blocker. [1]

   

(1r,7ar)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

(1r,7ar)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO5 (299.1733)


   

11-[(2r,5r,6r)-5-hydroxy-6-methylpiperidin-2-yl]undecanoic acid

11-[(2r,5r,6r)-5-hydroxy-6-methylpiperidin-2-yl]undecanoic acid

C17H33NO3 (299.246)


   

(2s,4e,6e,11e)-12-(pyridin-3-yl)dodeca-4,6,11-trien-2-yl acetate

(2s,4e,6e,11e)-12-(pyridin-3-yl)dodeca-4,6,11-trien-2-yl acetate

C19H25NO2 (299.1885)


   

[(7s,7as)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

[(7s,7as)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO5 (299.1733)


   

2-decyl-1-methylquinolin-4-one

2-decyl-1-methylquinolin-4-one

C20H29NO (299.2249)


   

(2e,6e,8e)-1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one

(2e,6e,8e)-1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one

C20H29NO (299.2249)


   

(3s,6r)-3-(1h-indol-3-ylmethyl)-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol

(3s,6r)-3-(1h-indol-3-ylmethyl)-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol

C17H21N3O2 (299.1634)


   

(2e,6e,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

(2e,6e,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

C20H29NO (299.2249)


   

(2s,4e,6e,8e)-12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate

(2s,4e,6e,8e)-12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate

C19H25NO2 (299.1885)


   

(1s,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

(1s,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

C19H25NO2 (299.1885)


   

1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

C19H25NO2 (299.1885)


   

2-(nonan-8-one)-4-methoxy-quinoline

NA

C19H25NO2 (299.1885)


{"Ingredient_id": "HBIN006130","Ingredient_name": "2-(nonan-8-one)-4-methoxy-quinoline","Alias": "NA","Ingredient_formula": "C19H25NO2","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "15680","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

2-(nonan-8-one)-n-methyl-4-quinolone

NA

C19H25NO2 (299.1885)


{"Ingredient_id": "HBIN006131","Ingredient_name": "2-(nonan-8-one)-n-methyl-4-quinolone","Alias": "NA","Ingredient_formula": "C19H25NO2","Ingredient_Smile": "CCCCCCC=CCC1=C(C(=O)C2=CC=CC=C2N1O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "15681","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-1h-pyrrolizin-1-yl]methyl (2r)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-1h-pyrrolizin-1-yl]methyl (2r)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO5 (299.1733)


   

11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

C20H29NO (299.2249)


   

2-undecyl-3h-quinolin-4-one

2-undecyl-3h-quinolin-4-one

C20H29NO (299.2249)


   

3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

C19H25NO2 (299.1885)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate

C16H29NO4 (299.2096)


   

(2e,9z)-n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid

(2e,9z)-n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid

C20H29NO (299.2249)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

C16H29NO4 (299.2096)


   

(3r)-3-[(2s)-butan-2-yl]-6-(1h-indol-3-ylmethyl)-3,6-dihydropyrazine-2,5-diol

(3r)-3-[(2s)-butan-2-yl]-6-(1h-indol-3-ylmethyl)-3,6-dihydropyrazine-2,5-diol

C17H21N3O2 (299.1634)


   

n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid

n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid

C20H29NO (299.2249)


   

(1r,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

(1r,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one

C19H25NO2 (299.1885)


   

(2e,4e,6e)-12-(pyridin-3-yl)dodeca-2,4,6-trien-1-yl acetate

(2e,4e,6e)-12-(pyridin-3-yl)dodeca-2,4,6-trien-1-yl acetate

C19H25NO2 (299.1885)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbut-2-enamide

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbut-2-enamide

C19H25NO2 (299.1885)


   

12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate

12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate

C19H25NO2 (299.1885)


   

n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

C20H29NO (299.2249)


   

(1s,2s,4s,6r,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

(1s,2s,4s,6r,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

C20H29NO (299.2249)


   

(2e,6z,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

(2e,6z,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

C20H29NO (299.2249)


   

[(7s,7as)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

[(7s,7as)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO5 (299.1733)


   

( )-intermedine

( )-intermedine

C15H25NO5 (299.1733)


   

(2z,6z,8z,12e)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

(2z,6z,8z,12e)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid

C20H29NO (299.2249)


   

(7as)-1-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate

(7as)-1-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate

C15H25NO5 (299.1733)


   

3-(1h-indol-3-ylmethyl)-6-(sec-butyl)-3,6-dihydropyrazine-2,5-diol

3-(1h-indol-3-ylmethyl)-6-(sec-butyl)-3,6-dihydropyrazine-2,5-diol

C17H21N3O2 (299.1634)


   

(1s,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

(1s,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

C16H29NO4 (299.2096)


   

9-(4-methoxyquinolin-2-yl)nonan-2-one

9-(4-methoxyquinolin-2-yl)nonan-2-one

C19H25NO2 (299.1885)


   

(2s,5e,8e,10e)-12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate

(2s,5e,8e,10e)-12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate

C19H25NO2 (299.1885)


   

(1s,2s,4s,6r,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol

(1s,2s,4s,6r,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol

C20H29NO (299.2249)


   

1-methyl-2-(8-oxononyl)quinolin-4-one

1-methyl-2-(8-oxononyl)quinolin-4-one

C19H25NO2 (299.1885)


   

(2e,7z)-1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one

(2e,7z)-1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one

C20H29NO (299.2249)


   

12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate

12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate

C19H25NO2 (299.1885)


   

(1s,2s,4s,6s,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol

(1s,2s,4s,6s,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol

C20H29NO (299.2249)


   

(1s,4r,12r,15r)-15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium

(1s,4r,12r,15r)-15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium

[C19H27N2O]+ (299.2123)


   

(1s,2s,4s,6s,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

(1s,2s,4s,6s,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol

C20H29NO (299.2249)


   

1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one

1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one

C20H29NO (299.2249)


   

(7z)-1-(pyrrol-1-yl)hexadec-7-en-10-yn-1-one

(7z)-1-(pyrrol-1-yl)hexadec-7-en-10-yn-1-one

C20H29NO (299.2249)


   

(3r,6s)-3-[(2s)-butan-2-yl]-6-(1h-indol-3-ylmethyl)-3,6-dihydropyrazine-2,5-diol

(3r,6s)-3-[(2s)-butan-2-yl]-6-(1h-indol-3-ylmethyl)-3,6-dihydropyrazine-2,5-diol

C17H21N3O2 (299.1634)


   

(1r,7ar)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

(1r,7ar)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO5 (299.1733)


   

3-(1h-indol-3-ylmethyl)-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol

3-(1h-indol-3-ylmethyl)-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol

C17H21N3O2 (299.1634)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate

C16H29NO4 (299.2096)


   

11-(5-hydroxy-6-methylpiperidin-2-yl)undecanoic acid

11-(5-hydroxy-6-methylpiperidin-2-yl)undecanoic acid

C17H33NO3 (299.246)


   

1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one

1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one

C20H29NO (299.2249)


   

hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-(1-hydroxyethyl)-4-methylpentanoate

hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-(1-hydroxyethyl)-4-methylpentanoate

C16H29NO4 (299.2096)


   

(2z,4e)-3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

(2z,4e)-3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

C19H25NO2 (299.1885)


   

1-hydroxy-3-methyl-2-[(2e)-non-2-en-1-yl]quinolin-4-one

1-hydroxy-3-methyl-2-[(2e)-non-2-en-1-yl]quinolin-4-one

C19H25NO2 (299.1885)


   

15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium

15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium

[C19H27N2O]+ (299.2123)


   

1-hydroxy-3-methyl-2-(non-2-en-1-yl)quinolin-4-one

1-hydroxy-3-methyl-2-(non-2-en-1-yl)quinolin-4-one

C19H25NO2 (299.1885)


   

1-(pyrrol-1-yl)hexadec-7-en-10-yn-1-one

1-(pyrrol-1-yl)hexadec-7-en-10-yn-1-one

C20H29NO (299.2249)


   

hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate

hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate

C16H29NO4 (299.2096)


   

7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2,3-dihydroxy-2-isopropylbutanoate

7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2,3-dihydroxy-2-isopropylbutanoate

C15H25NO5 (299.1733)